Low-dose Agalsidase Beta (cas 104138-64-9) treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial
-
Add time:08/01/2019 Source:sciencedirect.com
BackgroundFabry disease is a rare, X-linked, lifelong progressive lysosomal storage disorder. Severely deficient α-galactosidase A activity in males is associated with the classic phenotype with early-onset, multisystem manifestations evolving to vital organ complications during adulthood. We assessed the ability of 2 low-dose Agalsidase Beta (cas 104138-64-9) regimens to lower skin, plasma, and urine globotriaosylceramide (GL-3) levels, and influence clinical manifestations in male pediatric Fabry patients.
We also recommend Trading Suppliers and Manufacturers of Agalsidase Beta (cas 104138-64-9). Pls Click Website Link as below: cas 104138-64-9 suppliers
Prev:Solubilities of disperse dyes of blue 79:1, red 82 and modified yellow 119 in supercritical carbon dioxide and nitrous oxide
Next:Non-clinical evaluation of JR-051 as a biosimilar to Agalsidase Beta (cas 104138-64-9) for the treatment of Fabry disease) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information